Results 31 to 40 of about 527 (122)
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]
Background
Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction ...Melloni, C, Sherrid, MV, Cooper, R, Bering, P, Sharma, A, Wei, J, Bekfani, T, Collado, E, Habib, G, Wojakowski, W, Stoerk, S, Sarswat, N, Raymer, D, Desai, M, Nassif, ME, Yang, H, Zeng, Q, Paz, O, Musumeci, B, Weiner, S, Choudhury, L, Pavia, PG, Raman, B, Arad, M, Ravi, S, Symanski, JD, Mitter, S, Thune, J, Owens, D, Ahmad, F, Owens, AT, Drakos, S, Asher, C, Piltz, X, Jensen, M, Hidalgo Urbano, RJ, Kramer, C, Geske, J, Saberi, S, Naidu, S, Hagège, A, Tome Esteban, MT, Lhermusier, T, Turer, A, Lyle, M, Abraham, TP, Elliott, P, Wang, A, Moss, N, Coats, CJ, Wheeler, M, Mitrovic, V, Wang, J, Trochu, J-N, Amin, A, Shu, Y, Charron, P, Schulze, PC, Alvarez, AG, Bach, R, Hong, K, Nagueh, SF, Wang, Y, Darlington, A, Yuan, Z, Brinkley, DM, Zenker, M, Zhang, Y, Rincón Diaz, LM, McGrew, F, Rowin, E, Ma, C, Ripoll Vera, TV, Oreziak, A, Rader, F, Tao, L, Zemanek, D, Metra, M, Masri, A, Toste, A, Cheng, X, Bundgaard, H, Brandenburg, S, Barriales-Villa, R, Reant, P, Merkely, B, Dudek, D, Jani, S, Jacoby, DL, Mogensen, J, Lakdawala, N, Bradlow, W, Shao, C, Knackstedt, C, Meder, B, Emdin, M, Bastos, JM, Gimeno Blanes, JR, Yu, Z, Emani, S, Maurer, M, Alsidawi, S, Martinez, M, Bilen, O, Sen, S, Wever-Pinzon, O, Markowitz, J, Michels, M, Maron, MS, Olivotto, I, Chen, M, Heitner, SB, Marian, A, Edelman, F, Zfat-Zwas, D, Coats, C, Hannawi, B, Seidler, T, Nielsen, C, Solomon, SD, Rassaf, T, Donal, E, Logeart, D, Afshar, K, Rader, AT, Halabi, M, Garcia-Pavia, P, Tower-Rader, A, Lakdawala, NK, Wong, T, Canepa, M, Enciso, JS, Hussain, Z, Mahmod, M, Massera, D, Kelly, J, Pantazis, A, Li, X, Targetti, M, Fermin, D +139 morecore +2 more sourcesAficamten and Cardiopulmonary Exercise Test Performance [PDF]
Importance
Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM ...Sherrid, MV, Bering, P, Cooper, R, Sharma, A, Fraser, R, Elliott, PM, Thune, JJ, Collado, E, Bekfani, T, Kupfer, S, Habib, G, Wojakowski, W, Sarswat, N, Stoerk, S, Raymer, D, Resnic, F, Amin, AS, Mesquita Bastos, JA, Habib, M, Barriales Villa, R, Nassif, ME, Ripoll Vera, TVV, Musumeci, B, Paz, O, Phelan, D, Choudhury, L, Claggett, BL, Arad, M, Zwas, D, Owens, D, Ahmad, F, Cocca-Spofford, D, Owens, AT, Asher, C, Edelmann, F, Piltz, X, Lewis, GD, Hidalgo Urbano, RJ, Jensen, M, Kramer, C, Geske, J, Saberi, S, Naidu, S, Tome Esteban, MT, Lhermusier, T, Turer, A, Lyle, M, Abraham, TP, Wang, A, Moss, N, Coats, CJ, Mitrovic, V, Trochu, J-N, Charron, P, Garcia Pavia, P, Schulze, PC, Garcia Alvarez, A, Nagueh, SF, Darlington, A, Silva Enciso, J, Campain, J, Markowitz, JS, Ma, C, Kelly, JP, Rader, F, Oreziak, A, Zemanek, D, Wheeler, MT, Metra, M, Masri, A, Kulac, IJ, Hagege, AA, Giverts, I, Bundgaard, H, Meng, L, Wohltman, A, Barriales-Villa, R, Marian, AJ, Reant, P, Merkely, B, Dudek, D, Nielsen, CD, Gimeno, JR, Jani, S, Jacoby, DL, Mogensen, J, Bach, RG, Bradlow, W, Knackstedt, C, Meder, B, Emdin, M, Gimeno Blanes, JR, Emani, S, Malik, FI, O'Neill, T, Akinboboye, O, Martinez, M, Bilen, O, Sen, S, Wever-Pinzon, O, Michels, M, Landsteiner, I, Maron, MS, Olivotto, I, Heitner, SB, Toste Batista, AM, Desai Y, M, McGinnis, S, Lee, MMY, Coats, C, Hannawi, B, Seidler, T, Tower-Rader, AF, McGrew, FA, Solomon, SD, Rassaf, T, Logeart, D, Halabi, M, Wong, T, Lakdawala, NK, Canepa, M, Brinkley, D, Hussain, Z, Veselka, J, Maurer, MS, Mahmod, M, Moreno, FM, Pantazis, A, Targetti, M, Griskowitz, C, Newlands, C, Fermin, D, Rincon Diaz, LM +132 morecore +3 more sourcesExercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy:SEQUOIA-HCM Baseline Characteristics and Study Design [PDF]
, 2023 Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening .Jacoby, Daniel L, Cardim, Nuno, Malik, Fady I, Owens, Anjali T, Düngen, Hans-Dirk, Düngen, Hans Dirk, Oreziak, Artur, Michels, Michelle, Jacoby, Daniel L., Malik, Fady I., Lee, Matthew M Y, Heitner, Stephen B., Wohltman, Amy, Ma, Chang Sheng, Michels, Michelle; id_orcid, Heitner, Stephen B, Jacoby, Daniel L, Ma, Chang-Sheng, Coats, Caroline J., Lewis, Gregory D, Garcia-Pavia, Pablo, Watkins, Hugh C, Watkins, Hugh C., Lee, Matthew M.Y., Hagège, Albert A., Masri, Ahmad, Abraham, Theodore P, Meng, Lisa, Abraham, Theodore P., Tfelt-Hansen, Jacob, Maron, Martin S., Veselka, Josef, Kupfer, Stuart, Arad, Michael, Hagège, Albert A, Maron, Martin S, Owens, Anjali T., SEQUOIA-HCM Investigators, Coats, Caroline J, Choudhury, Lubna, Lewis, Gregory D., Olivotto, Iacopo +41 morecore +2 more sourcesPharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model [PDF]
, 2023 Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the Stern, Joshua A, Maureen S. Oldach, Joanna L. Kaplan, Darren T. Hwee, Sharpe, Ashley N, Victor Rivas, Malik, Fady I, Kaplan, Joanna L, Kovacs, Samantha L, Morgan, Bradley P, Harris, Samantha P, Hwee, Darren T, Rivas, Victor, Samantha L. Kovacs, Oldach, Maureen S, Bradley P. Morgan, Joshua A. Stern, Fady I. Malik, Samantha P. Harris, Ashley N. Sharpe +19 morecore +1 more sourceA New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]
, 2023 In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors Sepp, Róbert, Pálinkás, Eszter Dalma, Eszter Dalma Pálinkás, Iacopo Olivotto, Róbert Sepp, Olivotto, Iacopo +5 morecore +2 more sourcesAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]
Background:One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction ...Cardim, Nuno, Watkins, Hugh, Düngen, Hans-Dirk, Düngen, Hans Dirk, Oreziak, Artur, Michels, Michelle, Jacoby, Daniel L., Malik, Fady I., Solomon, Scott D., Heitner, Stephen B., Wohltman, Amy, Ma, Chang Sheng, Michels, Michelle; id_orcid, Ma, Chang-Sheng, Coats, Caroline J., Investigators, SEQUOIA-HCM., Garcia-Pavia, Pablo, Lee, Matthew M.Y., Hagège, Albert A., Masri, Ahmad, Meng, Lisa, Abraham, Theodore P., Tfelt-Hansen, Jacob, Claggett, Brian, Maron, Martin S., Januzzi, James L., Veselka, Josef, Kupfer, Stuart, Barriales-Villa, Roberto, Arad, Michael, Van Sinttruije, Marion, Owens, Anjali T., Spertus, John A., Nassif, Michael E., Choudhury, Lubna, Lewis, Gregory D., Olivotto, Iacopo, Lee, Matthew M Y, Nassif, Michael E, Lewis, Gregory D, Spertus, John A, Maron, Martin S, SEQUOIA-HCM Investigators, Malik, Fady I, Owens, Anjali T, Solomon, Scott D, Jacoby, Daniel L, Heitner, Stephen B, Januzzi, James L, Abraham, Theodore P, Hagège, Albert A, Coats, Caroline J +51 morecore +2 more sourcesTranslating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights
The Journal of Physiology, EarlyView.Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi +18 morewiley +1 more sourceIntegrative simulation analysis of myocardial ischaemia–reperfusion injury
The Journal of Physiology, Volume 604, Issue 18, Page 7640-7662, 15 September 2026.Abstract figure legend A comprehensive mathematical model of ventricular myocyte was developed to gain insights into the mechanisms underlying cardiac ischaemia–reperfusion injury. The model integrates excitation–contraction (E–C) coupling, cytosolic and mitochondrial pH regulation, pH dependence of major E–C coupling components and cellular energy ...Takao Shimayoshi, Ayako Takeuchi, Satoshi Matsuoka +2 morewiley +1 more sourceMetabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics
The Journal of Physiology, Volume 604, Issue 13, Page 5316-5341, 1 July 2026.Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran +4 morewiley +1 more sourceWhy Septal Thickness Does Not Tell the Whole Story: A Surgeon’s Reappraisal of Dynamic Outflow Obstruction in Hypertrophic Cardiomyopathy
Journal of Cardiac Surgery, Volume 2026, Issue 1, 2026.Background
For more than half a century, left ventricular outflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy (HCM) has been understood primarily as a consequence of septal hypertrophy. However, the correlation between septal thickness and obstruction severity is inconsistent, and cardiac myosin inhibitors can markedly reduce, and in many ...Yong Cui, Zhenzhen Wang, Meijuan Yan, Sandeep Sainathan +3 morewiley +1 more source
